BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 12839971)

  • 21. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.
    Deroanne CF; Bonjean K; Servotte S; Devy L; Colige A; Clausse N; Blacher S; Verdin E; Foidart JM; Nusgens BV; Castronovo V
    Oncogene; 2002 Jan; 21(3):427-36. PubMed ID: 11821955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
    Fong TA; Shawver LK; Sun L; Tang C; App H; Powell TJ; Kim YH; Schreck R; Wang X; Risau W; Ullrich A; Hirth KP; McMahon G
    Cancer Res; 1999 Jan; 59(1):99-106. PubMed ID: 9892193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
    Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Huber J; Nakatani T; Tsujinoue H; Yanase K; Imazu H; Fukui H
    Hepatology; 2002 Apr; 35(4):834-42. PubMed ID: 11915029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.
    Murakami K; Sakukawa R; Sano M; Hashimoto A; Shibata J; Yamada Y; Saiki I
    Clin Cancer Res; 1999 Sep; 5(9):2304-10. PubMed ID: 10499597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SU6668, a multitargeted angiogenesis inhibitor.
    Hoekman K
    Cancer J; 2001; 7 Suppl 3():S134-8. PubMed ID: 11779084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
    Guo Y; Wang S; Hoot DR; Clinton SK
    J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.
    Dalal S; Berry AM; Cullinane CJ; Mangham DC; Grimer R; Lewis IJ; Johnston C; Laurence V; Burchill SA
    Clin Cancer Res; 2005 Mar; 11(6):2364-78. PubMed ID: 15788688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion.
    Mallery SR; Morse MA; Wilson RF; Pei P; Ness GM; Bradburn JE; Renner RJ; Schuller DE; Robertson FM
    J Cell Biochem; 2003 May; 89(1):133-43. PubMed ID: 12682914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
    Ning S; Laird D; Cherrington JM; Knox SJ
    Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
    Laird AD; Christensen JG; Li G; Carver J; Smith K; Xin X; Moss KG; Louie SG; Mendel DB; Cherrington JM
    FASEB J; 2002 May; 16(7):681-90. PubMed ID: 11978732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells.
    Benndorf R; Böger RH; Ergün S; Steenpass A; Wieland T
    Circ Res; 2003 Sep; 93(5):438-47. PubMed ID: 12881481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
    Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of human NK cell lines by vascular endothelial growth factor and receptor VEGFR-1 (FLT-1).
    Chen WS; Kitson RP; Goldfarb RH
    In Vivo; 2002; 16(6):439-45. PubMed ID: 12494887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo.
    Riccioni T; Cirielli C; Wang X; Passaniti A; Capogrossi MC
    Gene Ther; 1998 Jun; 5(6):747-54. PubMed ID: 9747454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas.
    Angelov L; Salhia B; Roncari L; McMahon G; Guha A
    Cancer Res; 1999 Nov; 59(21):5536-41. PubMed ID: 10554031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
    Ou XM; Li WC; Liu DS; Li YP; Wen FQ; Feng YL; Zhang SF; Huang XY; Wang T; Wang K; Wang X; Chen L
    Int Immunopharmacol; 2009 Jan; 9(1):70-9. PubMed ID: 18976720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
    Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
    Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.
    Litz J; Sakuntala Warshamana-Greene G; Sulanke G; Lipson KE; Krystal GW
    Lung Cancer; 2004 Dec; 46(3):283-91. PubMed ID: 15541812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.